About Nova-EPO
Nova-EPO is a novel fusion protein of EPO polypeptide and a mutated Fc fragment of human IgG that exhibits significantly prolonged blood half-life. Nova-EPO was created with Genova’s proprietary technology for engineering long-acting proteins. The DNA and amino acid sequences of Nova-EPO have been patented in several major jurisdictions around the world.
The blood half-life of Nova-EPO is extended to 35 hours. The blood half-life of the naturally occurring EPO polypeptide is 8 hours and the blood half-life of Dabopoietin (Aranesp), developed by Amgen and approved by the United States FDA, is 24 hours. Nova-EPO in anemic animal models showed superior anti-anemia effects with lower required injection frequency compared to Aranesp (US7,625,564 B2). Currently, Nova-EPO is in the pre-clinical development stage.
The blood half-life of Nova-EPO is extended to 35 hours. The blood half-life of the naturally occurring EPO polypeptide is 8 hours and the blood half-life of Dabopoietin (Aranesp), developed by Amgen and approved by the United States FDA, is 24 hours. Nova-EPO in anemic animal models showed superior anti-anemia effects with lower required injection frequency compared to Aranesp (US7,625,564 B2). Currently, Nova-EPO is in the pre-clinical development stage.
About Nova-GM-CSF
Nova-GM-CSF is a novel fusion protein of GM-CSF polypeptide and a mutated Fc fragment of human IgG that exhibits significantly prolonged blood half-life. Nova-GM-CSF was created with Genova’s proprietary technology for engineering long-acting proteins. The DNA and amino acid sequences of Nova-GM-CSF have been patented in the United States. The mutated immunoglobulin hinge region can be used for engineering long-acting fusion proteins and has been patented in the United States (US8,067,548 B2). Currently, Nova-GM-CSF is in the pre-clinical development stage.
